IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

Interleukin-6 (IL-6) is a cytokine with many activities. It has functions in the regulation of the immune system and the nervous system. Furthermore, IL-6 is involved in liver regeneration and in the metabolic control of the body. On target cells, IL-6 binds to an 80 kDa IL-6 receptor (IL-6R). The complex of IL-6 and IL-6R associates with a second protein, gp130, which thereupon dimerizes and initiates intracellular signaling. Whereas gp130 is expressed on all cells, IL-6R is only present on few cells in the body including hepatocytes and some leukocytes. Cells, which do not express IL-6R cannot respond to the cytokine, since gp130 alone has no measurable affinity for IL-6. Interestingly, a soluble form of IL-6R (sIL-6R) comprising the extracellular portion of the receptor can bind IL-6 with a similar affinity as the membrane bound IL-6R. The complex of IL-6 and sIL-6R can bind to gp130 on cells, which do not express the IL-6R, and which are unresponsive to IL-6. This process has been called trans-signaling. Here I will review published evidence that IL-6 trans-signaling is pro-inflammatory whereas classic IL-6 signaling via the membrane bound IL-6R is needed for regenerative or anti-inflammatory activities of the cytokine. Furthermore, the detailed knowledge of IL-6 biology has important consequences for therapeutic strategies aimed at the blockade of the cytokine IL-6.

[1]  B. Jenkins,et al.  Acquiring signalling specificity from the cytokine receptor gp130. , 2004, Trends in genetics : TIG.

[2]  S. Hsiao,et al.  IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. , 2011, Cancer research.

[3]  M. Neurath,et al.  Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25− T Cells1 , 2007, The Journal of Immunology.

[4]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[5]  D. Wallach,et al.  Soluble cytokine receptors are present in normal human urine , 1989, The Journal of experimental medicine.

[6]  F. DeLeo.  Attractive shedding. , 2007, Blood.

[7]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[8]  R. Kyle,et al.  Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. , 1992, Cytokine.

[9]  M. Spehlmann,et al.  IL-6-Dependent Mucosal Protection Prevents Establishment of a Microbial Niche for Attaching/Effacing Lesion-Forming Enteric Bacterial Pathogens1 , 2008, The Journal of Immunology.

[10]  Stefan Rose-John,et al.  ADAM17: a molecular switch to control inflammation and tissue regeneration. , 2011, Trends in immunology.

[11]  J. Scheller,et al.  No inhibition of IL-27 signaling by soluble gp130. , 2005, Biochemical and biophysical research communications.

[12]  Ana D. Lopez,et al.  Maintenance of Pluripotency in Human Embryonic Stem Cells Is STAT3 Independent , 2004, Stem cells.

[13]  P. Schirmacher,et al.  Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. , 1998, The American journal of pathology.

[14]  J. Scheller,et al.  Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor* , 2011, The Journal of Biological Chemistry.

[15]  M. Neurath,et al.  Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. , 2007, International immunology.

[16]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[17]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[18]  S. Rose-John,et al.  Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells , 2002, AIDS.

[19]  M. Sata,et al.  Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble–IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model , 2009, The Journal of Immunology.

[20]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[21]  S. Rose-John,et al.  Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. , 1998, Blood.

[22]  P. Heinrich,et al.  Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. , 1993, The Journal of biological chemistry.

[23]  P. Heinrich,et al.  The soluble interleukin‐6 receptor is generated by shedding , 1993, European journal of immunology.

[24]  P. Rosenstiel,et al.  Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model* , 2011, Critical care medicine.

[25]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[26]  S. Rose-John,et al.  Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. , 1999, Glia.

[27]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[28]  Cindy L. Miller,et al.  Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Stefan Rose-John,et al.  Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. , 2011, European journal of cell biology.

[30]  J. Scheller,et al.  Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.

[31]  S. Rose-John,et al.  Sympathetic neurons can produce and respond to interleukin 6. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Rose-John,et al.  Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Scheller,et al.  Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. , 2008, Blood.

[34]  U. Klingmüller,et al.  Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. , 2006, Molecular biology of the cell.

[35]  J. Scheller,et al.  Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis1 , 2009, The Journal of Immunology.

[36]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[37]  J. Scheller,et al.  Forced Homo- and Heterodimerization of All gp130-Type Receptor Complexes Leads to Constitutive Ligand-independent Signaling and Cytokine-independent Growth , 2010, Molecular biology of the cell.

[38]  J. Scheller,et al.  Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. , 2012, Immunobiology.

[39]  S. Rose-John,et al.  Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Stefan Rose-John,et al.  Virokines in the Pathogenesis of Cancer: Focus on Human Herpesvirus 8 , 2004, Annals of the New York Academy of Sciences.

[41]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[42]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[43]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[44]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[45]  S. Rose-John,et al.  Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor , 1996, Infection and immunity.

[46]  M. Sata,et al.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice , 2006, Gut.

[47]  M. Meads,et al.  Kaposi's Sarcoma-associated Herpesvirus-encoded Viral Interleukin-6 Is Secreted and Modified Differently Than Human Interleukin-6 , 2004, Journal of Biological Chemistry.

[48]  Mark Woodward,et al.  Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012 .

[49]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[50]  Simon A. Jones,et al.  Brief Definitive Report C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding , 1999 .

[51]  T. Hirano,et al.  Studies on the structure and regulation of the human hepatic interleukin-6 receptor. , 1990, European journal of biochemistry.

[52]  S. Rose-John,et al.  Hitting a complex target: an update on interleukin-6 trans-signalling , 2012, Expert opinion on therapeutic targets.

[53]  M. Rincón,et al.  Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells1 , 2008, The Journal of Immunology.

[54]  Toshio Tanaka,et al.  Therapeutic targeting of the interleukin-6 receptor. , 2012, Annual review of pharmacology and toxicology.

[55]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[56]  S. Rose-John,et al.  In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. , 1998, Journal of immunology.

[57]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[58]  P. Galle,et al.  IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-61 , 2000, The Journal of Immunology.

[59]  C. Fielding,et al.  Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.

[60]  S. Boekholdt,et al.  The interleukin-6 pathway and atherosclerosis , 2012, The Lancet.

[61]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[62]  G. Yancopoulos,et al.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. , 1993, Blood.

[63]  P. Heinrich,et al.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. , 1994, Journal of immunology.

[64]  M. Goldsmith,et al.  A Kaposi’s Sarcoma-associated Herpesvirus-encoded Cytokine Homolog (vIL-6) Activates Signaling through the Shared gp130 Receptor Subunit* , 1997, The Journal of Biological Chemistry.

[65]  M. Neurath,et al.  Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis , 2000 .

[66]  J. Scheller,et al.  Loss of CD4+ T Cell IL-6R Expression during Inflammation Underlines a Role for IL-6 Trans Signaling in the Local Maintenance of Th17 Cells , 2010, The Journal of Immunology.

[67]  C. Fielding,et al.  Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. , 2007, Blood.

[68]  P. Heinrich,et al.  Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. , 1992, Biochemical and biophysical research communications.

[69]  S. Rose-John,et al.  Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. , 1999, Journal of immunology.

[70]  K. Garcia,et al.  Structure of an Extracellular gp130 Cytokine Receptor Signaling Complex , 2001, Science.

[71]  P. Heinrich,et al.  Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. , 1994, The Journal of biological chemistry.

[72]  Stefan Rose-John,et al.  Abrogation of Viral Interleukin-6 (vIL-6)-Induced Signaling by Intracellular Retention and Neutralization of vIL-6 with an Anti-vIL-6 Single-Chain Antibody Selected by Phage Display , 2006, Journal of Virology.

[73]  Stefan Rose-John,et al.  Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.

[74]  C. Peschle,et al.  Interleukin‐6 serum levels in patients with gynecological tumors , 1994, International journal of cancer.

[75]  J. Scheller,et al.  The IL-6/sIL-6R complex as a novel target for therapeutic approaches , 2007, Expert opinion on therapeutic targets.

[76]  P. Schirmacher,et al.  Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6–sIL-6R Double Transgenic Mice , 1997, The Journal of experimental medicine.

[77]  E. Wolf,et al.  The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6 , 1996, The Journal of experimental medicine.

[78]  Stefan Rose-John,et al.  The human interleukin‐6 (IL‐6) receptor exists as a preformed dimer in the plasma membrane , 2003, FEBS letters.

[79]  N. Krug,et al.  The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. , 2005, The Journal of clinical investigation.

[80]  J. Scheller,et al.  Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 Receptor , 2009, Journal of Virology.

[81]  P. Galle,et al.  Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. , 2000, European journal of biochemistry.

[82]  G. Ciliberto,et al.  Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. , 1994, Blood.

[83]  P. Heinrich,et al.  Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells , 2005, Journal of Cell Science.

[84]  P. Heinrich,et al.  Differential shedding of the two subunits of the interleukin‐6 receptor , 1993, FEBS letters.

[85]  W. Klapper,et al.  HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. , 2012, Blood.

[86]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[87]  Jennifer G. Robinson,et al.  The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.

[88]  L. D. Ward,et al.  Identification and Characterization of Two Distinct Truncated Forms of gp130 and a Soluble Form of Leukemia Inhibitory Factor Receptor α-Chain in Normal Human Urine and Plasma* , 1998, The Journal of Biological Chemistry.

[89]  K. Yasukawa,et al.  Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. , 1996, Leukemia research.

[90]  P. Musiani,et al.  Coexpression of IL‐6 and soluble IL‐6R causes nodular regenerative hyperplasia and adenomas of the liver , 1998, The EMBO journal.

[91]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[92]  K. Yasukawa,et al.  Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. , 1992, Journal of immunology.

[93]  J. Bazan,et al.  Haemopoietic receptors and helical cytokines. , 1990, Immunology today.

[94]  C. Fielding,et al.  Viral IL-6 Blocks Neutrophil Infiltration during Acute Inflammation1 , 2005, The Journal of Immunology.

[95]  S. Rose-John,et al.  IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3 , 2011, The Journal of Immunology.

[96]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[97]  J. Scheller,et al.  ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. , 2010, Biochimica et biophysica acta.

[98]  F. Neipel,et al.  Human herpesvirus 8 encodes a homolog of interleukin-6 , 1997, Journal of virology.

[99]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[100]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[101]  J. Scheller,et al.  gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. , 2006, Biochemical and biophysical research communications.

[102]  J. Born,et al.  Sleep enhances IL‐6 trans‐signaling in humans , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[103]  T. Taniguchi,et al.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. , 1988, Science.

[104]  D. Lauffenburger,et al.  Ligand/Receptor Signaling Threshold (LIST) Model Accounts for gp130‐Mediated Embryonic Stem Cell Self‐Renewal Responses to LIF and HIL‐6 , 2002, Stem cells.